Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MSRA divergent transcript (MSRA-DT) refers to a long non-coding RNA molecule produced by bidirectional transcription at the promoter region of the *MSRA* gene. Divergent transcripts are a widespread genomic phenomenon in mammals, typically arising from active promoters and often associated with regulatory genes[1][3][5]. These RNAs are antisense to the coding gene, may participate in chromatin modulation, and can influence transcriptional regulation and sometimes post-transcriptional events such as mRNA stability[1][3][5]. However, as a class rather than a well-characterized unique molecule, "MSRA divergent transcript" does not meet criteria for a canonical therapeutic target, lacks an independently defined gene symbol, and is not recognized as a direct subject of drug targeting or disease biomarker utility. If more context or a specific transcript ID is provided, more detailed functional annotation may be possible.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MSRA divergent transcript (MSRA-DT).